Global Insulin Glargine Market 2022-2028

December 2022 | 62 pages | ID: GEC31D1DB269EN
Gen Consulting Company

Abstracts

The global insulin glargine market is projected to rise by USD 0.0 billion by 2028, according to a new report by Gen Consulting Company. It is anticipated to expand at a CAGR of 0 percent during the forecast period.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global insulin glargine market. It traces the market’s historic and forecast market growth. The report identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches. This study also provides an analysis of the impact of the COVID-19 crisis on the insulin glargine industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the type, and region. The global market for insulin glargine can be segmented by type: Lantus, Basaglar, Toujeo, Soliqua, insulin glargine biosimilars. The Lantus segment was the largest contributor to the global insulin glargine market in 2021. Insulin glargine market is further segmented by region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. According to the research, Asia-Pacific had the largest share in the global insulin glargine market.

Market Segmentation

By type: Lantus, Basaglar, Toujeo, Soliqua, insulin glargine biosimilars

By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America

The report explores the recent developments and profiles of key vendors in the Global Insulin Glargine Market, including Biocon Limited, Eli Lilly And Company, JULPHAR, Novo Nordisk AS, Sanofi S.A., among others.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period

This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report

• To analyze and forecast the market size of the global insulin glargine market.
• To classify and forecast the global insulin glargine market based on type, region.
• To identify drivers and challenges for the global insulin glargine market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global insulin glargine market.
• To identify and analyze the profile of leading players operating in the global insulin glargine market.

Why Choose This Report

• Gain a reliable outlook of the global insulin glargine market forecasts from 2022 to 2028 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints
Impact of COVID-19 pandemic

PART 5. MARKET BREAKDOWN BY TYPE

Lantus
Basaglar
Toujeo
Soliqua
Insulin glargine biosimilars

PART 6. MARKET BREAKDOWN BY REGION

North America
Europe
Asia-Pacific
MEA (Middle East and Africa)
Latin America

PART 7. KEY COMPANIES

Biocon Limited
Eli Lilly And Company
JULPHAR
Novo Nordisk AS
Sanofi S.A.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER